Improving glycaemic control in young people with type 1 diabetes (T1D) remains challenging. No study has specifically evaluated efficacy and usability of DexCom G6 CGM in this cohort. Adolescents and young adults with T1D (age 16 to 25 years old) on multiple daily insulin injections (MDI) or insulin pump therapy (CSII) were recruited into an 8-week, open-label, randomised, crossover design clinical trial. Participants monitored daily glucose levels either with DexCom G6 CGM or self-monitoring blood glucose (SMBG) in random order during two 8-week study periods. Blinded CGM was applied for a 3-week period during the control phase. Data from 29 participants were analysed (mean±SD age 21.3±2.3years, 16 [55.2%] female, baseline A1c 78.7±14.4mmol/mol, diabetes duration 13.1±5.1years, BMI 25.4±4.7kg/m2, CSII/MDI users= 17/12). The primary outcome, time spent in target range (70-180mg/dl) as recorded by CGM was significantly higher during CGM compared to the control period (see Table). CGM use reduced mean sensor glucose and time spent above target. A1c level was also reduced by 8.9mmol/mol (95% CI -4.3 to -13.3, p<0.005) in the CGM period. Time spent below target increased on CGM, no episodes of severe hypoglycaemia or DKA occurred. Median sensor use was 86% during the study.
In conclusion, CGM use improves time in target and A1c levels in young people with T1D.
H. Thabit: Research Support; Self; Dexcom, Inc. W.M. Mubita: None. C. Fullwood: None. S. Azmi: None. A. Urwin: None. I.M. Doughty: None. L. Leelarathna: Advisory Panel; Self; Abbott Laboratories, Medtronic, Novo Nordisk A/S, Sanofi. Research Support; Self; Dexcom, Inc., Novo Nordisk A/S. Speaker’s Bureau; Self; Medtronic. J. Paul-Prabhu: None.
Dexcom, Inc.
